Do you want to read an article? Please log in or register.
CFTR Modulator Use Is Associated with Higher Hemoglobin Levels in Individuals with Cystic Fibrosis
Pulmonary Fibrosis
Related content
Pulmonary Fibrosis
Impact of a cystic fibrosis transmembrane conductance regulator (CFTR) modulator on high-dose ibuprofen therapy in pediatric cystic fibrosis patients
Pediatr Pulmonol.
Bruch BA, Singh SB, Ramsey LJ, Starner TD
doi: 10.1002/ppul.24024.
Pulmonary Fibrosis
Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment
J Cyst Fibros.
Nagy B Jr, Bene Z, Fejes Z, Heltshe SL, Reid D, Ronan NJ, McCarthy Y, Smith D, Nagy A, Joseloff E, Balla G, Kappelmayer J, Macek M Jr, Bell SC, Plant BJ, Amaral MD, Balogh I
doi: 10.1016/j.jcf.2018.08.013.
RECOMMENDED
Pulmonary Fibrosis
Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Med
Dagenais RVE, Su VCH, Quon BS
doi: 10.3390/jcm10010023
Pulmonary Fibrosis
CFTR modulator theratyping: Current status, gaps and future directions
J Cyst Fibros.
Clancy JP, Cotton CU, Donaldson SH, Solomon GM, VanDevanter DR, Boyle MP, Gentzsch M, Nick JA, Illek B, Wallenburg JC, Sorscher EJ, Amaral MD, Beekman JM, Naren AP, Bridges RJ, Thomas PJ, Cutting G, Rowe S, Durmowicz AG, Mense M, Boeck KD, Skach W, Penland C, Joseloff E, Bihler H, Mahoney J, Borowitz D, Tuggle KL
doi: 10.1016/j.jcf.2018.05.004.
RECOMMENDED
Pulmonary Fibrosis
Challenges in the use of highly effective modulator treatment for cystic fibrosis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
J Cyst Fibros
Ramos KJ, Pilewski JM, Taylor-Cousar JL
doi: 10.1016/j.jcf.2021.01.007
Pulmonary Fibrosis
Correlating CFTR Function with Clinical Features to Inform Precision Treatment of Cystic Fibrosis
Am J Respir Crit Care Med.
McCague AF, Raraigh KS, Pellicore MJ, Davis-Marcisak EF, Evans TA, Han ST, Lu Z, Joynt AT, Sharma N, Castellani C, Collaco JM, Corey M, Lewis MH, Penland CM, Rommens JM, Stephenson AL, Sosnay PR, Cutting GR
doi: 10.1164/rccm.
Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation
J Pediatr.
Farrell PM, White TB, Ren CL, Hempstead SE, Accurso F, Derichs N, Howenstine M, McColley SA, Rock M, Rosenfeld M, Sermet-Gaudelus I, Southern KW, Marshall BC, Sosnay PR
doi: 10.1016/j.jpeds.2016.09.064.
AsthmaPulmonary Fibrosis
Pulmonary ventilation imaging in asthma and cystic fibrosis using oxygen-enhanced 3D radial ultrashort echo time MRI
J Magn Reson Imaging.
Zha W, Kruger SJ, Johnson KM, Cadman RV, Bell LC, Liu F, Hahn AD, Evans MD, Nagle SK, Fain SB
doi: 10.1002/jmri.25877.
Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial
Lancet Respir Med.
Ratjen F, Hug C, Marigowda G, Tian S, Huang X, Stanojevic S, Milla CE, Robinson PD, Waltz D, Davies JC; VX14-809-109 investigator group
doi: 10.1016/